NGNE (Neurogene) Marketable Securities: $119.02 Mil (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $39.54
! 4 Warning Signs
View Full Analysis

What is Neurogene Marketable Securities?

Neurogene NGNE -7.49% 12 Marketable Securities is $119.02 Mil as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Neurogene's Marketable Securities for the quarter that ended in Mar. 2026 was $119.02 Mil.

Neurogene's annual Marketable Securities increased from Dec. 2023 ($48.95 Mil) to Dec. 2024 ($175.82 Mil) but then declined from Dec. 2024 ($175.82 Mil) to Dec. 2025 ($165.17 Mil).

Neurogene  (NAS:NGNE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Neurogene Marketable Securities Related Terms

Neurogene Marketable Securities Historical Data

* Premium members only.

The historical data trend for Neurogene's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Marketable Securities Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 48.95 175.82 165.17

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.83 215.71 194.41 165.17 119.02
NGNE
12GF Score
Neurogene Inc NGNE
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $119.02 Mil mean?
Neurogene (NGNE) has a Marketable Securities of $119.02 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Neurogene and its competitors.
Is Neurogene's Marketable Securities too high?
Neurogene's current Marketable Securities is $119.02 Mil. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Marketable Securities compare to STRO and OCGN?
Neurogene's Marketable Securities of $119.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Neurogene and its competitors. Neurogene's current Marketable Securities is $119.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Marketable Securities of $119.02 Mil. The current Marketable Securities is $119.02 Mil. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Neurogene (NGNE), the current Marketable Securities is $119.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.54
Price